OSRH · OSR Health, Inc.
$0.42
-0.03 (-6.69%)
At close · Jul 24
Market Cap
$15.80M
Shares
35.10M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.91M
-17.7%
FY2025
Net Income
-$27.06M
-1022.4%
FY2025
Gross Margin
20.4%
-2.6pp
FY2025
Operating Margin
-631.01%
-299.8pp
FY2025
Diluted EPS
-$0.80
+83.3%
FY2025
Operating Cash Flow
-$4.33M
-134%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $2.63M | $2.91M | $3.53M | — | — | — | |
| $2.04M | $2.31M | $2.72M | — | — | — | |
| — | $97.53K | $113.47K | — | — | — | |
| $584.5K | $592.91K | $811.24K | — | — | — | |
| — | 20.4% | 22.98% | — | — | — | |
| — | $318.45K | $161.16K | — | — | — | |
| — | — | $3.52M | $1.83M | — | — | |
| $19.67M | $18.93M | $12.5M | $1.83M | $35.39K | $3308 | |
| — | $9.3M | $9.63M | — | — | — | |
| -$19.09M | -$18.34M | -$11.69M | -$1.83M | -$35.39K | -$3308 | |
| — | -631.01% | -331.2% | — | — | — | |
| $521.02K | $506.2K | $51.34K | — | — | — | |
| $77.04K | $63.88K | $21.29K | $2.78M | — | — | |
| — | — | $1.41M | $2.78M | — | — | |
| -$21.42M | -$28.89M | -$11.89M | $944.59K | — | — | |
| — | -$1.83M | -$1.56M | $540.81K | — | — | |
| -$19.13M | -$27.06M | -$2.41M | $403.78K | -$35.39K | -$3308 | |
| — | -931.19% | -68.29% | — | — | — | |
| — | -$9.05M | — | — | — | — | |
| -$9.55M | -$18.01M | -$10.33M | — | — | — | |
| -$11.53M | -$14.03M | -$10.28M | — | — | — | |
| USD/shares | — | -$0.92 | -$4.79 | $0.05 | -$0.01 | — |
| USD/shares | — | -$0.80 | -$4.79 | $0.05 | -$0.01 | — |
| shares | — | 19.52M | 2.16M | 7.69M | 1.5M | 1.5M |
| shares | — | 22.56M | 2.16M | 7.72M | 1.5M | 1.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $72.23M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×